Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 4/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74682 | 0.92 | ESR1 (0.42) | ESR1TTRCHEK1DAPK3RET | |
| Hydrochloric Acid SCHEMBL11680474 | 0.84 | ESR1 (0.36) | ESR1TTRCHEK1DAPK3RET | |
| SCHEMBL20437119 | 0.81 | ESR1 (0.38) | ESR1 | |
| SCHEMBL6349366 | 0.78 | ESR1 (0.50) | ESR1MEN1KMT2ACYP1A2HIF1A | |
| SCHEMBL20443843 | 0.77 | TTR (0.42) | TTRCHEK1DAPK3RETPDGFRB | |
| SCHEMBL18855312 | 0.77 | CHEK1 (0.42) | ESR1TTRCHEK1DAPK3RET | |
| SCHEMBL9248538 | 0.76 | ESR1 (0.48) | ESR1MEN1KMT2ACYP1A2HIF1A | |
| SCHEMBL5865868 | 0.76 | ESR1 (0.48) | ESR1MEN1KMT2ACYP1A2HIF1A | |
| SCHEMBL10026836 | 0.75 | ESR1 (0.58) | ESR1MEN1KMT2ACYP1A2HIF1A | |
| SCHEMBL3238817 | 0.74 | ALDH1A1 (0.68) | ESR1MEN1KMT2ACYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091434-B2 | Type III deiodinase inhibitors and uses thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-10435365-B2 | Type III deiodinase inhibitors and uses thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2019-10-08 | — | — | US | disclosed |
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2018-08-02 | — | — | US | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-8877729-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110177160-A1 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | MARINA BIOTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7939505-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ESR1 2200/4885TTR 2412/4885CHEK1 4392/4885 |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | ESR1 2952/4885TTR 372/4885CHEK1 2853/4885 |
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | TPO, DPP3, HSD17B3 | ESR1 1861/4885TTR 1819/4885CHEK1 3725/4885 |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | AADAT, AARS1, ABAT | ESR1 3716/4885TTR 156/4885CHEK1 2796/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | ESR1 2200/4885TTR 2412/4885CHEK1 4392/4885 |
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | SNRPE, SNRPA, ADAR | ESR1 2883/4885TTR 2923/4885CHEK1 1612/4885 |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | SLC27A2, LYPLA2, SLC27A1 | ESR1 3767/4885TTR 2996/4885CHEK1 4452/4885 |
| US-11091434-B2 | Type III deiodinase inhibitors and uses thereof | TPO, DPP3, HSD17B3 | ESR1 1861/4885TTR 1819/4885CHEK1 3725/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | ESR1 1939/4885TTR 2076/4885CHEK1 4388/4885 |
| US-10435365-B2 | Type III deiodinase inhibitors and uses thereof | TPO, DPP3, HSD17B3 | ESR1 1861/4885TTR 1819/4885CHEK1 3725/4885 |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC47A2 | ESR1 3742/4885TTR 3036/4885CHEK1 4635/4885 |
| US-20110177160-A1 | Amino acid lipids and uses thereof | AADAT, AARS1, ABAT | ESR1 3716/4885TTR 156/4885CHEK1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.